Skip to main
APGE

APGE Stock Forecast & Price Target

APGE Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 58%
Buy 25%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Apogee Therapeutics Inc. is positioned to capitalize on the growing market for biologics in the inflammatory and immunology sectors, as evidenced by the substantial sales figures of leading competitors like Dupixent, which generated over $14 billion in 2024 with projections for continued growth. The company's focus on developing optimized antibody programs, such as APG777, aims to enhance efficacy and dosing compared to existing therapies, thereby tapping into the expanding revenue potential within the atopic dermatitis and other related markets. Furthermore, recent analyses suggest an increased probability of success for APG777 in asthma treatment, reinforcing confidence in Apogee's ability to compete effectively amid a crowded landscape of established players.

Bears say

Apogee Therapeutics faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from developmental setbacks within its pipeline programs, which may lead to revisions in financial estimates. The company is also at risk of encountering unexpected safety signals, regulatory approval failures, and commercialization challenges, all of which could hinder its growth and sustainability in the market. Additionally, the absence of revenue generation increases the financial strain on Apogee, complicating the company's ability to fund ongoing research and development efforts.

APGE has been analyzed by 12 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 25% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apogee Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apogee Therapeutics Inc (APGE) Forecast

Analysts have given APGE a Buy based on their latest research and market trends.

According to 12 analysts, APGE has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $109.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $109.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apogee Therapeutics Inc (APGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.